Immediate Impact

73 standout
Sub-graph 1 of 21

Citing Papers

Ultrasound-Based Micro-/Nanosystems for Biomedical Applications
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
2 intermediate papers

Works of Christopher Dakhil being referenced

Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.
2018
Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
2018

Author Peers

Author Last Decade Papers Cites
Christopher Dakhil 255 190 125 20 374
Paloma Martín-Martorell 273 180 49 27 410
Landon C. Brown 190 242 87 27 356
Xiangying Meng 218 159 73 31 342
Fawaz Almutairi 129 229 113 20 353
Angela Chan 190 92 76 26 339
BC Lembersky 291 169 157 14 437
Olivier Marpeau 106 104 76 15 438
Allison Tyler 189 210 104 22 380
G. Baciarello 272 201 75 18 411
Adithya Chennamadhavuni 329 116 34 18 420

All Works

Loading papers...

Rankless by CCL
2026